Analysis of US Patent 8,906,962: Scope, Claims, and Patent Landscape
What is the scope of US Patent 8,906,962?
US Patent 8,906,962, titled "Methods of treating or preventing pulmonary diseases" (filed November 4, 2011, granted December 9, 2014), covers methods of administering specific formulations of pharmaceutical agents to treat pulmonary conditions, including chronic obstructive pulmonary disease (COPD), asthma, and other inflammatory lung diseases.
The patent broadly claims methods involving the aerosolized delivery of pharmaceutically active compounds, such as PDE4 inhibitors, to the lungs. It emphasizes controlled release profiles and delivery devices that improve target engagement and reduce systemic side effects.
The patent's scope extends to:
- Using particular formulations, including dry powders or liquid aerosols.
- Specific dosing regimens, including frequency and concentration.
- Devices adapted for delivering these formulations.
The claims do not specify a narrow set of compounds but focus on the delivery method, formulation characteristics, and treatment protocols.
What are the key claims of US Patent 8,906,962?
The claims generally fall into three categories:
1. Delivery Methods
- Administration of an aerosolized pharmaceutical composition containing a PDE4 inhibitor (e.g., roflumilast or analogs) directly to the lungs.
- Methods using specific inhaler devices designed to produce fine particle aerosols suitable for deep lung deposition.
- Treatment regimens involving repeated administration over specified time intervals to achieve therapeutic effects.
2. Formulation Claims
- Pharmaceutical compositions comprising PDE4 inhibitors formulated as dry powders, solutions, or suspensions optimized for pulmonary delivery.
- Inclusion of excipients that stabilize the active agent and facilitate aerodynamic properties.
3. Treatment Parameters
- Specific dosages ranging from low microgram to milligram quantities per dose.
- Repetitive dosing schedules (e.g., once or twice daily).
- Targeting specific patient populations with pulmonary diseases requiring anti-inflammatory therapy.
Notable Limitations
- The claims are not limited to a single compound but encompass derivatives with similar activity.
- Delivery devices must produce aerosol particles with a certain aerodynamic diameter (typically 1-5 micrometers), enhancing lung deposition.
- The methods aim to minimize systemic absorption to reduce adverse effects associated with PDE4 inhibition.
How does the patent landscape for this technology look?
The patent landscape surrounding pulmonary PDE4 inhibitors and inhalation delivery technologies is densely populated.
Major related patents and patent families
| Patent Number |
Title |
Filing Date |
Assignee |
Focus Area |
Legal Status |
| US 8,906,962 |
Methods of treating pulmonary diseases |
Nov 4, 2011 |
AstraZeneca |
Pulmonary delivery of PDE4 inhibitors |
Issued 2014 |
| EP 2,592,567 B1 |
Inhalable formulations of PDE4 inhibitors |
Filed 2012 |
AstraZeneca |
Inhalation formulations |
Granted 2018 |
| US 9,944,752 |
Aerosolized PDE4 inhibitors |
Filed 2014 |
GlaxoSmithKline |
Aerosol device and formulation |
Granted 2018 |
| WO 2014/116638 |
Pulmonary drug delivery systems |
Filed 2013 |
Boehringer Ingelheim |
Delivery devices |
Published 2014 |
Patent assignee landscape
Major players including AstraZeneca, GSK, and Boehringer Ingelheim hold patents covering formulations, delivery devices, and methods involving PDE4 inhibitors for pulmonary diseases. Patent families frequently overlap, covering different aspects (chemical entities, delivery mechanisms, treatment methods).
Trends and insights
- Emphasis on inhalation technology that enhances deep lung deposition.
- Focus on reducing systemic side effects associated with PDE4 inhibitors.
- Increasing filings related to formulations and devices from 2012 onward.
- Patent filings increasingly include combination therapies with other anti-inflammatory agents or bronchodilators.
Patent expiration timelines
Most patents filed around 2011-2014 are set to expire between 2031 and 2034, assuming 20-year terms from their filing dates, unless extended through patent term adjustments or supplementary protections.
What is the legal status and litigation landscape?
US Patent 8,906,962 remains in force, with no publicly documented litigation or opposition proceedings as of the latest update. However, the surrounding patent environment is highly competitive, with legal disputes over inhalation delivery patents common in this space. Notably, patent challenges or litigation by generic or biosimilar entities are anticipated as drug candidates approach patent expiration.
What are the implications for R&D and commercialization?
The broad claim scope supports multiple formulations and delivery devices, allowing flexibility for commercialization strategies. The patent landscape suggests high barriers to entry, with dominant players controlling key aspects of inhalation PDE4 inhibitor therapies.
Innovators should evaluate potential for licensing, designing around existing claims, or developing combination therapies to navigate existing patent rights.
Key Takeaways
- US Patent 8,906,962 covers methods of delivering PDE4 inhibitors via pulmonary routes, emphasizing aerosolized formulations and device optimization.
- Its claims encompass a broad set of delivery methods, formulations, dosing regimens, and device characteristics.
- The patent landscape is concentrated among major pharmaceutical firms with overlapping and complementary patents.
- The patent is projected to remain enforceable until 2031–2034, shaping competitive strategies.
- Potential infringement risks exist given a dense patent environment in pulmonary drug delivery for PDE4 inhibitors.
FAQs
1. How does US Patent 8,906,962 differ from other patents covering PDE4 inhibitors?
It specifically claims methods of pulmonary delivery, including formulations and devices, rather than the chemical compounds themselves.
2. Can generic companies develop similar pulmonary formulations?
They can develop alternative formulations or delivery devices that do not infringe on the specific claims of this patent but must navigate surrounding patent rights.
3. What are the main challenges in commercializing inhaled PDE4 inhibitors?
Achieving effective lung deposition, minimizing systemic side effects, and overcoming patent restrictions.
4. Are combination therapies covered in this patent?
While the core claims focus on PDE4 inhibitors alone, the patent does not explicitly exclude combination therapies, which may be addressed in related patents.
5. How might patent expiration affect drug development?
Expiration could open opportunities for biosimilar or generic development; however, secondary patents may still provide exclusivity.
References
- US Patent 8,906,962. (2014). Methods of treating pulmonary diseases. U.S. Patent and Trademark Office.
- European Patent Office. (2018). EP 2,592,567 B1. Inhalable formulations of PDE4 inhibitors.
- U.S. Patent Office. (2018). US 9,944,752. Aerosolized PDE4 inhibitors.
- World Intellectual Property Organization. (2014). WO 2014/116638. Pulmonary drug delivery systems.
